NUVB vs. SLN, ANAB, YMAB, SVRA, IRON, PHAR, PAHC, DNTH, SIGA, and EOLS
Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Silence Therapeutics (SLN), AnaptysBio (ANAB), Y-mAbs Therapeutics (YMAB), Savara (SVRA), Disc Medicine (IRON), Pharming Group (PHAR), Phibro Animal Health (PAHC), Dianthus Therapeutics (DNTH), SIGA Technologies (SIGA), and Evolus (EOLS). These companies are all part of the "pharmaceutical preparations" industry.
Nuvation Bio (NYSE:NUVB) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Nuvation Bio received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. Likewise, 71.43% of users gave Nuvation Bio an outperform vote while only 70.00% of users gave Silence Therapeutics an outperform vote.
In the previous week, Nuvation Bio had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Nuvation Bio and 0 mentions for Silence Therapeutics. Nuvation Bio's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.
Silence Therapeutics has higher revenue and earnings than Nuvation Bio. Silence Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Nuvation Bio has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.
Nuvation Bio currently has a consensus target price of $6.60, suggesting a potential upside of 106.25%. Silence Therapeutics has a consensus target price of $57.25, suggesting a potential upside of 154.44%. Given Silence Therapeutics' higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Nuvation Bio.
Nuvation Bio has a net margin of 0.00% compared to Silence Therapeutics' net margin of -171.41%. Nuvation Bio's return on equity of -12.21% beat Silence Therapeutics' return on equity.
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 36.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Nuvation Bio beats Silence Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Nuvation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvation Bio Competitors List
Related Companies and Tools
